The utilization of spirocyclic scaffolds in novel drug discovery

Expert Opinion on Drug Discovery

Volumn 11, Issue 9, 2016, Pages 831-834

  Zheng, Ya Jun ^a   Tice, Colin M ^a  

^a Vitae Pharmaceuticals   (United States)

Author keywords

Drug discovery; spirocycles; spirocyclic scaffolds; structure based drug design

Indexed keywords

ENZYME; ENZYME INHIBITOR; IBUTAMOREN; LEDIPASVIR; MOLECULAR SCAFFOLD; ROLAPITANT; TOFOGLIFLOZIN; UBROGEPANT; ZOLIFLODACIN; HETEROCYCLIC COMPOUND; SPIRO COMPOUND;

DRUG DEVELOPMENT; DRUG TARGETING; EDITORIAL; PRIORITY JOURNAL; CHEMISTRY; DRUG DESIGN; HUMAN; PROCEDURES; SYNTHESIS;

DRUG DESIGN; DRUG DISCOVERY; HETEROCYCLIC COMPOUNDS; HUMANS; SPIRO COMPOUNDS;

EID: 84973650162     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1080/17460441.2016.1195367     Document Type: Editorial

References (28)

1. F.F.Taylor, W.W.Faloon The role of potassium in the natriuretic response to a steroidal lactone (SC-9420). J Clin Endocrinol Metab. 1959;19:1683–1687. doi:10.1210/jcem-19-12-1683.
2. E.M.Carreira, T.C.Fessard. Four-membered ring-containing spirocycles:synthetic strategies and opportunities. Chem Rev (Washington, DC, U S.). 2014;114:8257–8322. doi:10.1021/cr500127b.•• Important paper focused on four-membered spirocycles.
3. M.Moossavi, B.Bagheri, R.K.Scher. Systemic antifungal therapy. Dermatol Clin. 2001;19:35–52.
4. M.M.C.Lo, C.S.Neumann, S.Nagayama, et al. A library of spirooxindoles based on a stereoselective three-component coupling reaction. J Am Chem Soc. 2004;126:16077–16086. doi:10.1021/ja045089d.
5. T.J.Ritchie, S.J.F.MacDonald. The impact of aromatic ring count on compound developability:are too many aromatic rings a liability in drug design? Drug Discov Today. 2009;14:1011–1020. doi:10.1016/j.drudis.2009.07.014.• Important article on the impact of aromatic ring count on developability.
6. W.R.Pitt, D.M.Parry, B.G.Perry, et al. Heteroaromatic rings of the future. J Med Chem. 2009;52:2952–2963. doi:10.1021/jm801513z.
7. Y.Zheng, C.M.Tice, S.B.Singh. The use of spirocyclic scaffolds in drug discovery. Bioorg Med Chem Lett. 2014;24:3673–3682. doi:10.1016/j.bmcl.2014.06.081.•• Review of recent spirocyclic scaffolds in drug discovery (2011–2014).
8. J.Yuan, S.Venkatraman, Y.Zheng, et al. Structure-based design of β-site APP cleaving enzyme 1 (BACE1) inhibitors for the treatment of Alzheimer’s disease. J Med Chem. 2013;56:4156–4180. doi:10.1021/jm301659n.• Important review of SBDD for BACE1.
9. T.A.Dineen, K.Chen, A.C.Cheng, et al. Inhibitors of β-site amyloid precursor protein cleaving enzyme (BACE1):identification of (S)-7-(2-fluoropyridin-3-yl)-3-((3-methyloxetan-3-yl)ethynyl)-5′H-spiro[chromeno[2,3-b]pyridine-5,4′-oxazol]-2′-amine (AMG-8718). J Med Chem. 2014;57:9811–9831. doi:10.1021/jm5012676.
10. A.A.Thomas, K.W.Hunt, B.Newhouse, et al. 8-Tetrahydropyran-2-yl chromans:highly selective beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors. J Med Chem. 2014;57:10112–10129. doi:10.1021/jm5015132.
11. Merck Sharp & Dohme Corp., USA. Preparation of C-6 spirocarbocyclic iminothiadiazine dioxides as BACE inhibitors useful in treatment of diseases. WO2015094930 (2015).
12. A.Lodola, R.Castelli, M.Mor, et al. Fatty acid amide hydrolase inhibitors:a patent review (2009-2014). Expert Opin Ther Pat. 2015;25:1247–1266. doi:10.1517/13543776.2015.1067683.• Important review of fatty acid amide hydrolase inhibitor-related patents.
13. M.J.Meyers, S.A.Long, M.J.Pelc, et al. Discovery of novel spirocyclic inhibitors of fatty acid amide hydrolase (FAAH). Part 2. Discovery of 7-azaspiro[3.5]nonane urea PF-04862853, an orally efficacious inhibitor of fatty acid amide hydrolase (FAAH) for pain. Bioorg Med Chem Lett. 2011;21:6545–6553. doi:10.1016/j.bmcl.2011.08.048.
14. D.A.Griffith, D.W.Kung, W.P.Esler, et al. Decreasing the rate of metabolic ketone reduction in the discovery of a clinical acetyl-CoA carboxylase inhibitor for the treatment of diabetes. J Med Chem. 2014;57:10512–10526. doi:10.1021/jm5016022.
15. G.S.Basarab, P.Doig, V.Galullo, et al. Discovery of novel DNA gyrase inhibiting spiropyrimidinetriones:benzisoxazole fusion with N-linked oxazolidinone substituents leading to a clinical candidate (ETX0914). J Med Chem. 2015;58:6264–6282. doi:10.1021/acs.jmedchem.5b00863.
16. S.F.Neelamkavil, S.Agrawal, T.Bara, et al. Discovery of MK-8831, a novel spiro-proline macrocycle as a pan-genotypic HCV-NS3/4a protease inhibitor. ACS Med Chem Lett. 2016;7:111–116. doi:10.1021/acsmedchemlett.5b00425.
17. A.A.Patchett, R.P.Nargund. Chapter 26. Privileged structures — an update. In Doherty AM, editor. Annual Reports in Medicinal Chemistry. Vol. 35. San Diego (CA):Academic Press; 2000. p. 289–298.
18. A.A.Patchett, R.P.Nargund, J.R.Tata, et al. Design and biological activities of L-163,191 (MK-0677):a potent, orally active growth hormone secretagogue. Proc Natl Acad Sci U S A. 1995;92:7001–7005.
19. Phase 2 clinical trials of MK-1602. [cited 2016 May15]. Available from: https://clinicaltrials.gov/ct2/results?term=MK-1602&pg=1
20. I.M.Bell. Calcitonin gene-related peptide receptor antagonists:new therapeutic agents for migraine. J Med Chem. 2014;57:7838–7858. doi:10.1021/jm500364u.
21. I.Olver. Role of rolapitant in chemotherapy-induced emesis. Lancet Oncol. 2015;16:1006–1007. doi:10.1016/S1470-2045(15)00096-0.
22. S.Fischer, C.Wiese, E.Grosse Maestrup, et al. Molecular imaging of σ receptors:synthesis and evaluation of the potent σ1 selective radioligand [18F]fluspidine. Eur J Nucl Med Mol Imaging. 2011;38:540–551. doi:10.1007/s00259-010-1658-z.
23. A.Johansson, C.Löfberg, M.Antonsson, et al. Discovery of (3-(4-(2-oxa-6-azaspiro[3.3]heptan-6-ylmethyl)phenoxy)azetidin-1-yl)(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)methanone (AZD1979), a melanin concentrating hormone receptor 1 (MCHr1) antagonist with favorable physicochemical properties. J Med Chem. 2016;59:2497–2511. doi:10.1021/acs.jmedchem.5b01797.
24. J.O.Link, J.G.Taylor, L.Xu, et al. Discovery of ledipasvir (GS-5885):a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. J Med Chem. 2014;57:2033–2046. doi:10.1021/jm401499g.
25. M.Belema, O.D.Lopez, J.A.Bender, et al. Discovery and development of hepatitis C virus NS5A replication complex inhibitors. J Med Chem. 2014;57:1643–1672. doi:10.1021/jm401793m.
26. S.Wang, W.Sun, Y.Zhao, et al. SAR405838:an optimized inhibitor of MDM2–p53 interaction that induces complete and durable tumor regression. Cancer Res. 2014;74:5855–5865. doi:10.1158/0008-5472.CAN-14-0799.
27. Y.Ohtake, T.Sato, T.Kobayashi, et al. Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem. 2012;55:7828–7840. doi:10.1021/jm300884k.
28. Vitae Pharmaceuticals, Inc., USA. Boehringer Ingelheim International GmbH. Preparation of spirocyclic azoles and azines as inhibitors of β-secretase (BACE). WO2010105179 (2010).